← Issue №17/ week of Oct 25, 2026/IBD

Fecal microbiota transplant in the treatment of inflammatory bowel diseases: new perspectives on delivery, mechanism, and clinical positioning.

From GI Signals issue №17: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

IBD review · Oct 24, 2026 · Inflamm Bowel Dis · IF 4.5

Fecal microbiota transplant in the treatment of inflammatory bowel diseases: new perspectives on delivery, mechanism, and clinical positioning.

Basic sciencemicrobiome
Clinical takeawayNo clinical action yet: a narrative review; FMT outcomes in IBD are variable, and clinical use beyond recurrent C. difficile infection remains limited.
What it foundFMT shows variable clinical outcomes in IBD compared to its high success in recurrent CDI, with evolving delivery strategies like oral capsules.
ContextChallenges current practice: FMT is established for recurrent CDI but remains investigational in IBD, with no consensus on its role in IBD treatment.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Javed A … Alexander JL · Inflammatory Bowel Diseases · IF 4.5 · PubMed ↗Permalink
← Read the whole of issue №17 Every paper GI Signals surfaces gets a page like this one. All issues